CoChat

The Association of Falling Insulin Requirements With Maternal Biomarkers and Placental Dysfunction: A Prospective Study of Women With Preexisting Diabetes in Pregnancy

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

OBJECTIVE To investigate the association of falling insulin requirements (FIR) among women with preexisting diabetes with adverse obstetric outcomes and maternal biomarkers longitudinally in pregnancy. RESEARCH DESIGN AND METHODS A multicenter prospective cohort study of 158 women (41 with type 1 diabetes and 117 with type 2 diabetes) was conducted. Women with FIR of ≥15% from the peak total daily dose after 20 weeks' gestation were considered case subjects (n = 32). The primary outcome was a composite of clinical markers of placental dysfunction (preeclampsia, small for gestational age [≤5th centile], stillbirth, premature delivery [<30 weeks], and placental abruption). Maternal circulating angiogenic markers (placental growth factor [PlGF] and soluble fms-like tyrosine kinase 1 [sFlt-1]), placental hormones (human placental lactogen, progesterone, and tumor necrosis factor-α), HbA1c, and creatinine were studied serially during pregnancy. RESULTS FIR ≥15% were associated with an increased risk of the composite primary outcome (odds ratio [OR] 4.38 [95% CI 1.9–10.3]; P < 0.001), preeclampsia (OR 6.76 [95% CI 2.7–16.7]; P < 0.001), and was more common among women with type 1 diabetes (36.6 vs. 14.5%; P = 0.002). Creatinine was modestly elevated among women with FIR ≥15%; however, there was no difference in HbA1c. The ratio of sFlt-1 to PlGF was significantly higher among women with FIR at 25, 30, and 36 weeks, with differences maintained in the subgroup that developed preeclampsia. There was no difference in placental hormones between the groups. CONCLUSIONS This is the first prospective study to associate FIR with altered expression of placental antiangiogenic factors and preeclampsia. FIR are an important clinical sign, among women with preexisting diabetes, that should alert the clinician to investigate underlying placental dysfunction.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc17-0391

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 55

Metadata

Authors
Padmanabhan, S., Lee, V. W., Mclean, M., Athayde, N., Lanzarone, V., Khoshnow, Q., Peek, M. J., & Cheung, N. W.
Affiliations
  • The University of Sydney (AU)
  • Blacktown & Mount Druitt Hospital (AU)
  • Westmead Hospital (AU)
  • Nepean Hospital (AU)
  • Australian National University (AU)
Corresponding author
Padmanabhan, Suja
Venue
Diabetes Care
Published
2017-08-10
Volume
40
Issue
10
Pages
1323-1330
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2742424235
Cited by
55
References
40
Citations by year
2026: 4 · 2025: 6 · 2024: 7 · 2023: 7 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 2
FWCI
4.20
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • ANU Open Research (Australian National University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
type 1 diabetes, type 2 diabetes, placental insufficiency, preeclampsia, angiogenic biomarkers, small for gestational age, stillbirth, placental abruption, human placental lactogen, placental hormones, maternal biomarkers, adverse obstetric outcomes
MeSH terms
Adult, Creatinine, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Infant, Infant, Small for Gestational Age, Insulin, Placenta, Placental Hormones, Pregnancy, Pregnancy Complications, Pregnancy in Diabetics, Pregnancy Outcome, Prospective Studies, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.